Alice Melão, MSc,  —

Articles by Alice Melão

DEA Clears Cannabinoid-derived Active Ingredient in Investigational Scleroderma Therapy EHP-101

The U.S. Drug Enforcement Administration (DEA) has cleared the use of the active ingredient in EHP-101, an investigational therapy for treating multiple sclerosis (MS) and systemic sclerosis (SSc), according to Emerald Health Pharmaceuticals, the therapy’s developer. After a detailed review, the regulatory agency has determined that the active pharmaceutical…